Oncology Central

Infographic: Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma


Click below to view our exclusive infographic, which depicts the rationale and design of the ongoing Phase III PIX306 study. This trial has been designed to evaluate the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma.

To view restricted content, please:

Leave A Comment